brl 42810 has been researched along with Body Weight in 3 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter, open-label study evaluated the single-dose pharmacokinetics and safety of a pediatric oral famciclovir (prodrug of penciclovir) formulation in infants aged 1 to 12 months with suspicion or evidence of herpes simplex virus infection." | 5.14 | Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. ( Blumer, J; Hamed, K; Kaiser, G; Rodriguez, A; Sallas, W; Sánchez, PJ, 2010) |
| "To develop a population pharmacokinetic model for penciclovir (famciclovir is a prodrug of penciclovir) in adults and children and suggest an appropriate dose for children." | 1.35 | Population pharmacokinetics and optimal design of paediatric studies for famciclovir. ( Aarons, L; Graham, G; Kaiser, G; Looby, M; Matthews, I; Ogungbenro, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blumer, J | 1 |
| Rodriguez, A | 1 |
| Sánchez, PJ | 1 |
| Sallas, W | 1 |
| Kaiser, G | 2 |
| Hamed, K | 1 |
| Ogungbenro, K | 1 |
| Matthews, I | 1 |
| Looby, M | 1 |
| Graham, G | 1 |
| Aarons, L | 1 |
| Thackray, AM | 1 |
| Field, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Open-label, Single-arm Study to Evaluate the Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections[NCT00448227] | Phase 2 | 18 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured by AUC(0-6h) - Area under the plasma concentration time curve from time zero up to 6 hours post dose (i.e. the time of the last sample). (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | (μg/mL)•h (Mean) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 2.22 |
| Famciclovir: Infants 3 to <6 Months | 3.16 |
| Famciclovir: Infants 6 to 12 Months | 8.77 |
Measured by AUC(0-tlast) - Area under the plasma concentration time curve from time zero to the last quantifiable concentration-timepoint. (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | (μg/mL)•h (Mean) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 2.09 |
| Famciclovir: Infants 3 to <6 Months | 3.16 |
| Famciclovir: Infants 6 to 12 Months | 8.68 |
Measured by Cmax - The maximum plasma concentration of study medication (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | μg/mL (Mean) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 0.69 |
| Famciclovir: Infants 3 to <6 Months | 0.74 |
| Famciclovir: Infants 6 to 12 Months | 3.24 |
Measured by Tmax - The time after administration of a drug when the maximum plasma concentration is reached. (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | hours (Median) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 1.00 |
| Famciclovir: Infants 3 to <6 Months | 4 |
| Famciclovir: Infants 6 to 12 Months | 1.02 |
"Assessed by the study personnel using a 5-point scale after dosing:~Very badly accepted/unacceptable: infant showed great displeasure, compromising use of formulation~Badly but accepted: infant showed displeasure with dosing but could be coaxed to take complete dose~Neither good nor bad: infant showed no apparent displeasure and with little effort was coaxed to take complete dose~Well accepted: infant appeared to enjoy the formulation and with little coaxing ingested most of dose~Very well accepted: infant appeared eager and ingested most of dose without special coaxing" (NCT00448227)
Timeframe: Immediately after dosing
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very badly / unacceptable | Badly but accepted | Neither good nor bad | Well accepted | Very well accepted | |
| Famciclovir: Infants 1 to <3 Months | 1 | 0 | 0 | 2 | 4 |
| Famciclovir: Infants 3 to <6 Months | 0 | 0 | 2 | 0 | 3 |
| Famciclovir: Infants 6 to 12 Months | 0 | 1 | 2 | 1 | 1 |
| Total | 1 | 1 | 4 | 3 | 8 |
"Assessed by the caregiver using a 5-point scale immediately after dosing:~Very badly accepted/unacceptable: infant showed great displeasure, compromising use of formulation~Badly but accepted: infant showed displeasure with dosing but could be coaxed to take complete dose~Neither good nor bad: infant showed no apparent displeasure and with little effort was coaxed to take complete dose~Well accepted: infant appeared to enjoy the formulation and with little coaxing ingested most of dose~Very well accepted: infant appeared eager and ingested most of dose without special coaxing" (NCT00448227)
Timeframe: Immediately after dosing
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very badly / unacceptable | Badly but accepted | Neither good nor bad | Well accepted | Very well accepted | |
| Famciclovir: Infants 1 to <3 Months | 1 | 0 | 0 | 2 | 4 |
| Famciclovir: Infants 3 to <6 Months | 0 | 0 | 2 | 0 | 3 |
| Famciclovir: Infants 6 to 12 Months | 0 | 1 | 1 | 2 | 1 |
| Total | 1 | 1 | 3 | 4 | 8 |
"Tolerability was assessed by the study personnel 30 minutes after dosing using the following scale:~Significant emesis occurred,~Infant spit out most of the dose ingesting less than half of what was administered,~Infant spit out some of the dose, but ingested at least 50% of what was administered,~Infant was able to ingest and retain the dose administered" (NCT00448227)
Timeframe: 30 minutes after dosing
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Significant emesis occurred | Spit out most of the dose, ingested less than half | Spit out some of the dose, ingested at least 50% | Able to ingest and retain dose | |
| Famciclovir: Infants 1 to <3 Months | 1 | 0 | 0 | 7 |
| Famciclovir: Infants 3 to <6 Months | 0 | 0 | 0 | 5 |
| Famciclovir: Infants 6 to 12 Months | 0 | 0 | 0 | 5 |
| Total | 1 | 0 | 0 | 17 |
1 trial available for brl 42810 and Body Weight
| Article | Year |
|---|---|
Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Body Weight; Capsules; Child; Chil | 2010 |
2 other studies available for brl 42810 and Body Weight
| Article | Year |
|---|---|
Population pharmacokinetics and optimal design of paediatric studies for famciclovir.
Topics: 2-Aminopurine; Adult; Age Factors; Antiviral Agents; Area Under Curve; Body Weight; Child; Child, Pr | 2009 |
Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Body Weight; Brain; Cell Culture Techniques; De | 1998 |